Pharmacy

AbbVie completes $10.9 billion acquisition of Apogee Therapeutics
AbbVie’s $10.9 billion Apogee deal deepens its immunology bet

AbbVie has completed its $10.9 billion acquisition of Apogee Therapeutics, gaining clinical-stage drugs for atopic dermatitis, asthma and other inflammatory diseases. The deal strengthens AbbVie’s immunology pipeline but is expected to dilute earnings until the next decade.

a laboratory setting featuring a pharmaceutical 3D printer
Pete Pharma is reshaping pharmaceutical compounding through 3D printing, linking innovation directly to real‑world use

“You miss every shot you don’t take.”
Marc Joiner does not treat that as just a slogan. It shapes his decisions and guides his career. Today, it forms the foundation of his work as Co-founder at Pete Pharma, where he leads pharmaceutical compounding in a new direction.

A woman holding a GLP-1 weight loss drug as manufacturers developing next-generation obesity and weight loss medicines.
The race to build the next generation of weight loss drugs

The obesity drug market is entering a new phase as pharmaceutical companies race to develop oral therapies, combination treatments and next-generation medicines. With forecasts pointing to a $100 billion annual market, competition is shifting from two dominant players to a much broader field of innovators.